Revelation Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REVB research report →
Companywww.revbiosciences.com
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
- CEO
- James Rolke
- IPO
- 2020
- Employees
- 8
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $4.26M
- P/E
- -0.35
- P/S
- 0.00
- P/B
- 0.27
- EV/EBITDA
- 0.91
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -107.66%
- ROIC
- -73.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,913,649 · 40.73%
- EPS
- $-23.95 · 72.68%
- Op Income
- $-9,070,814
- FCF YoY
- 54.91%
Performance & Tape
- 52W High
- $32.26
- 52W Low
- $0.88
- 50D MA
- $1.15
- 200D MA
- $4.04
- Beta
- -0.14
- Avg Volume
- 80.64K
Get TickerSpark's AI analysis on REVB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 30, 26 | Rolke James | other | 10,115 |
| Apr 30, 26 | Zygmont Chester Stanley III | other | 13,285 |
| Feb 3, 26 | ROPER JESS | other | 1,591 |
| Feb 3, 26 | Chawla Lakhmir S | other | 2,261 |
| Feb 3, 26 | CARVER JENNIFER | other | 1,661 |
| Feb 3, 26 | Rolke James | other | 8,521 |
| Feb 4, 26 | Zygmont Chester Stanley III | other | 13,100 |
| Jan 8, 26 | Rolke James | other | 532,829 |
| Jan 8, 26 | Zygmont Chester Stanley III | other | 78,145 |
| Jan 8, 26 | CARVER JENNIFER | other | 41,981 |
Our REVB Coverage
We haven't published any research on REVB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate REVB Report →